Translational Science Committee: Translating Molecular Insights into Clinical Practice: Recent Advances from NRG Oncology Trials

12/16/2025

Written by Adam P. Dicker, MD, PhD

Molecular Profiling Refines Treatment Approaches in Anaplastic Astrocytomas

Exciting findings from the NRG Oncology/RTOG 9813 trial demonstrate how modern molecular classification can transform our understanding of grade 3 astrocytomas and guide therapeutic decisions. This comprehensive analysis of a phase 3 study comparing radiation with temozolomide versus BCNU/CCNU reveals that applying 2021 WHO molecular criteria led to the reclassification of one-third of patients to higher-grade tumors, highlighting the critical importance of molecular diagnostics in neuro-oncology.

The study identified several key molecular markers that significantly impact prognosis. IDH1/2 mutations, MGMT promoter methylation, and ATRX mutations were each independently associated with improved survival outcomes, while TERT promoter mutations, EGFR amplification, and chromosome 7 gain/10 loss predicted poorer outcomes. Notably, the molecular grade proved to be a powerful prognostic indicator, with grade 3 patients achieving a median overall survival of 9.4 years compared to just 1.5 years for grade 4 patients.

Clinical Impact: These findings suggest that temozolomide may benefit IDH-mutant patients regardless of MGMT status, challenging conventional treatment paradigms. The data indicate that MGMT-unmethylated patients treated with RT and temozolomide achieved outcomes comparable to those of MGMT-methylated patients. This finding could expand treatment options for previously considered “unfavorable” molecular profiles. This molecular approach enables more precise risk stratification and personalized treatment selection for patients with anaplastic astrocytomas.  https://www.sciencedirect.com/science/article/pii/S0360301625002846?via%3Dihub 

Genomic Classifier Identifies Prostate Cancer Patients Who Benefit Most from Chemotherapy

The NRG Oncology/RTOG 0521 trial analysis represents a significant step forward in personalizing treatment for high-risk localized prostate cancer. Researchers validated the Decipher Genomic Classifier in pretreatment biopsy samples. They discovered that basal-luminal cellular subtypes can predict which patients derive the most significant benefit from adding docetaxel to definitive radiotherapy with androgen suppression.

The study analyzed 183 samples from the phase 3 trial and found that the Decipher GC was independently associated with both metastasis-free survival and distant metastasis events. The 10-year restricted mean survival time difference in overall survival with chemotherapy was 13.7 months for LP (p 0=.053) and 2.5 months for non-LP (p  =  0.63). A combined DNA methylation and RNA expression model outperformed standard WHO grading in predicting the response to radiotherapy.

Clinical Impact: These results provide a roadmap for more selective use of chemotherapy in high-risk prostate cancer. Rather than treating all high-risk patients uniformly, clinicians can now identify the subset—approximately 28% with LP tumors—most likely to benefit from treatment intensification with docetaxel. This precision approach has the potential to spare patients unlikely to benefit from chemotherapy while ensuring those who stand to gain receive optimal treatment. The findings support the incorporation of molecular profiling into standard clinical practice for risk stratification and treatment planning. https://www.sciencedirect.com/science/article/pii/S2588931125001038?via%3Dihub

Molecular Classification Transforms Surgical and Radiation Decision-Making in Meningiomas

A groundbreaking study analyzing 2,824 meningiomas, including 100 prospective cases from the NRG Oncology RTOG-0539 trial, demonstrates how molecular profiling can refine surgical and radiotherapeutic strategies. Using propensity score matching to minimize bias, researchers identified molecular biomarkers that predict treatment response and guide clinical decision-making.

The analysis confirmed that gross tumor resection improves progression-free survival across all molecular groups, with particular benefit for overall survival in proliferative meningiomas. Importantly, treating dural margins (Simpson grade 1/2) provided significant benefit compared to leaving margins untreated, though aggressive dural excision (grade 1) offered no substantial advantage over thermocoagulation alone (grade 2). The study identified proliferative meningiomas as largely radiotherapy-resistant, while immunogenic, NF2-wildtype, and hypermetabolic tumors responded favorably to RT.

The team developed and validated molecular prediction models using both DNA methylation and gene expression data that outperformed standard WHO grading in predicting radiotherapy response. These models, now publicly available, can provide individualized risk assessments to guide RT treatment decisions.

Clinical Impact: These findings challenge the historical surgical dogma of aggressive dural resection in every case, suggesting that thermocoagulation may achieve similar outcomes with potentially less risk to critical neurovascular structures. The identification of RT-resistant proliferative meningiomas—which can occur across all WHO grades—provides a rationale for molecularly informed clinical trials investigating alternative therapies. This precision approach enables surgeons to balance oncologic goals with surgical safety and efficacy. It helps radiation oncologists identify patients most likely to benefit from adjuvant treatment, ultimately improving outcomes while avoiding unnecessary treatment toxicity.
https://www.nature.com/articles/s41591-024-03167-4